Prof. Ningqiang Gong got his PhD from the department of Chemistry, Tsinghua University, China. He then worked as a postdoc in the Department of Bioengineering, University of Pennsylvania. Dr. Gong currently is a principal investigator at Division of Life Sciences and Medicine, University of Science and Technology of China. His research lies at the intersection of biomaterials, drug delivery, and genetic, protein, and cellular engineering, aiming to gain fundamental insights and provide therapeutic solutions to biomedical challenges in clinical settings. His focus spans various unmet clinical needs, including cancer immunotherapy resistance, recurrences, toxicities, side effects, among others. He has published more than 50 papers related to adoptive cell therapy, cancer vaccine, and cancer nanomedicine. (Nat. Biomed. Eng (2024) doi.org/10.1038/s41551-023-01147-6, Nat. Biomed. Eng 7, 1129–1141 (2023), Nat. Mater. 22, 1571–1580 (2023), Nat Commun. 12, 4964 (2021), Nat. Nanotechnol. 16, 25-36 (2021), Nat. Nanotechnol. 15, 1053–1064 (2020), Nat. Nanotechnol. 14, 379–387 (2019), Sci. Adv.5, eaaw6264(2019))